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ABSTRACT Small children with airway obstruction breathe with very low tidal volumes (VT) and high
respiratory rates (RRs). These extreme respiratory patterns affect drug delivery unpredictably through
valved holding chambers (VHCs).
We compared in an in vitro study the effectiveness of two VHCs, one small (140 mL, Optichamber
Diamond) and one large (350 mL, Babyhaler) without facemasks, to deliver salbutamol to filters
positioned between the VHC mouthpieces and a breathing simulator. Different tidal volumes (from 30 mL
to 200 mL) and RRs (25·min-1 and 50·min-1) were applied through a breathing simulator.
The amount of salbutamol delivered increased with increasing VT in both VHCs for both RRs (ρ>0.87
and p<0.001 for both devices at both rates). The effect of RR was not as evident, but drug delivery tended
to be higher at the higher rate. Drug delivery was significantly higher through the Optichamber Diamond
as compared with the Babyhaler at every combination of RR and VT up to a 12-fold difference.
We found marked differences in salbutamol delivery between the Babyhaler and Optichamber Diamond
VHCs. The delivered dose of salbutamol increased with increasing VT and RR with both VHCs but with
differences related to valve dead spaces. Instead of considering all VHCs equal in clinical paediatric
practice, each device should be tested in vitro with respiratory patterns relevant to small children with
respiratory difficulties.
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Children with respiratory problems are treated with inhaled drugs given via valved holding
chambers (VHCs). Efficacy can vary up to 12-fold between devices. The effectiveness of VHCs
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Introduction
Recurrent wheezing is most common before school age compared with any other age group [1].
Furthermore, acute exacerbations of asthma account for approximately 10% of the emergency visits in
children resulting in hospitalisation in 20–40% of cases [2]. In young children, inhaled bronchodilators
and corticosteroids are administered by pressurised metered dose inhalers (pMDIs). The use of valved
holding chambers (VHCs) improves drug delivery and precludes the need for coordination of actuation
and inhalation by holding the aerosol cloud to be released only during inhalation [3, 4].
There are numerous problems that physicians and caregivers encounter when treating small children with
inhaled medication delivered through a pMDI connected to a VHC. The only possible inhalation
technique in young children is tidal breathing. Infants and toddlers have highly variable tidal volumes
(VT) and respiratory rates (RRs). Particularly in the acute setting during an asthma attack or breathing
difficulty (when bronchodilators are most needed) it is not possible to instruct very young children on the
correct breathing pattern for optimal drug delivery. Breath holding is not possible in most children below
the age of 3 years. In addition, the drug delivery is greatly dependent on the pMDI and VHC combination
used. As a consequence, the child’s clinical response to inhaled medications might be very difficult
to predict.
The most important breathing parameters affecting the delivered dose of inhaled medications are RR, VT,
the duty cycle (inspiratory proportion of the breathing cycle, tI/ttot), and the peak inspiratory flow rate
(PIFR) that is determined by the three previous variables. Breathing pattern, VT, PIFR, and resting RR all
change with growth and development [5, 6]. VT in the first years of life, is approximately 7–10 mL·kg−1
of ideal body weight [6]. With increasing age, RR decreases (median breath·min−1 at <1 year is 37–44;
1–3 years is 25–38; 3–6 years is 22–26; and 6–12 years is 18–22 breath·min−1) [7] while VT increases.
During bronchoconstriction, VT decreases and RR increases, compared with normal and asthmatic
patients, have a higher range of variation in PIFR compared with healthy subjects [5]. PIFR is linearly
correlated with VT [5, 8] and drug delivery seems to increase with a rise in VT. Previous studies evaluating
drug delivery by VHCs have mainly been done with inspiratory flow rates of 20–60 L·min−1, and only a
few have used rates <10 L·min−1 [8–11]. However, low flow rates are clinically important, since children
below school age can have inspiratory flow rates as low as 2 L·min−1. Also, the optimal number of breaths
required to empty the VHC depends on the child’s VT, the volume of the VHC and the valve dead space.
Generally, 5–10 breaths are sufficient per actuation [3, 12].
Each VHC has its own unique features that are related to material, electrostatic and aerodynamic
characteristics, volume, dead space, and valve design. The behaviour of an aerosolised drug depends on the
VHC used [13, 14] and certain combinations of pMDI and VHC may result in drastic differences in dose
output [3, 10, 12, 15, 16]. In addition, drug delivery is dependent on the patient population under
investigation [17]. Inhaled drug delivery studies should evaluate each VHC with the particular target
population’s breathing pattern during normal and obstructive conditions.
There is a plethora of VHCs on the market with different material, design, volume, and overall
characteristics. A significant proportion of published studies evaluating and comparing the efficacy of
VHCs is funded by their manufacturers, causing a potential bias. In addition, only a handful of studies
have addressed the issue of the breathing patterns of small children especially in obstructive conditions. In
many countries, the most widely used VHC is the Babyhaler (BH) both in healthcare units and at home.
BH also represents a large-volume VHC model that has been used for a number of years in the acute care
of children. In contrast, the Optichamber Diamond (OD) represents a new type of VHC made of
nonconducting plastic with a relatively small valve dead space and small overall volume.
We used an in vitro setup with a filter interposed between the VHC and breathing simulator. This allows
multiple measurements to be performed reproducibly minimising confounding factors and focussing on
those parameters that are related specifically to the VHCs. Face masks were excluded from this study for
the same reason.
The main aims of this study were to 1) assess whether there are clinically significant advantages of a newer
and smaller type of VHC compared with an older and larger VHC and 2) to evaluate the effects of VT and
RR on drug delivery from a pMDI using VT and RRs that are relevant to small children with respiratory
difficulties.
Materials and methods
Device setup
Delivery of salbutamol sulfate generated by a pMDI (Ventoline Evohaler 1 mg·mL−1, Glaxo Wellcome
Production, Evreux, France) was measured through a small volume (140 mL OD, Philips Respironics, UK)
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and a large-volume (350 mL BH, GlaxoSmithKline, USA) plastic VHC. Three separate devices from
different manufacturing lots were used for both VHCs.
Prior to measurements all the VHC components were immersed in lukewarm water with detergent (Fairy
Liquid; Proctor & Gamble, Harrogate, UK), rinsed under running tap water, and left to air dry vertically.
A filter (PARI Respiratory Equipment, Inc., USA) was placed in a low-dead-space (10 mL) filter holder
and connected between the VHC mouth piece and the breathing simulator (Sinus Breathing Simulator;
PARI, Starnberg, Germany) (figure 1). The simulator produced alternating inspirations and expirations
with sinusoidal wave and a duty cycle (inspiratory proportion of the breathing cycle) of 0.5. The accuracy
of the breathing simulator was validated by a Fluke VT305 Gas Flow Analyzer (Fluke Biomedical, USA).
Measurement protocols
We used two different RRs (25 min−1 and 50 min−1) and five different VT (30 mL, 50 mL, 100 mL,
150 mL and 200 mL). The corresponding minute ventilations with mean and peak inspiratory flows at
each VT and RR are presented in table 1. At each combination of RR and VT, Ventolin was actuated and
salbutamol output was measured on three replications using each of three separate devices of both BH
and OD. Thus, nine measurements of salbutamol output at each combination of RR and VT are used in
the results.
Before each measurement sequence, pMDIs were primed by actuating those five times to waste. Before
every actuation the pMDI was shaken vigorously five times. The pMDI was then inserted into the VHC
and actuated once immediately at the start of inhalation. Salbutamol was left to accumulate into the filter
for eight breathing cycles. The filters were sealed until analysis with Parafilm M (Bemis Company, Inc.,
Oshkosh, WI, USA).
Filter analysis
Drug particles deposited on the filters at each measurement protocol were recovered and analysed by
high-performance liquid chromatography (HPLC) carried out by Emmace Consulting AB (Lund, Sweden).
The HPLC method was based on an internal standard methodology and the limit of quantitation (LOQ)
was determined as the peak height corresponding to 10 times the noise level. The LOQ was 2 µg.
FIGURE 1 Test rig. The filter was
placed in a filter holder and
connected between the valved
holding chamber mouth piece and
the breathing simulator.
TABLE 1 Measurement protocols used and corresponding mean and peak inspiratory flows
VT mL RR min−1 Minute ventilation
L·min−1
Mean inspiratory
flow L·min−1
Peak inspiratory
flow L·min−1
30 25 0.75 1.5 2.4
50 1.5 3.0 4.7
50 25 1.25 2.5 3.9
50 2.5 5.0 7.9
100 25 2.5 5.0 7.9
50 5.0 10.0 15.7
150 25 3.75 7.5 11.8
50 7.5 15.0 23.6
200 25 5.0 10.0 15.7
50 10.0 20.0 31.4
VT: tidal volume; RR: respiratory rate.
https://doi.org/10.1183/23120541.00158-2018 3
PAEDIATRIC PULMONOLOGY | P. CSONKA AND L. LEHTIMÄKI
The HPLC system (Agilent 1100) was fitted with the appropriate column (Symmetry (Waters), C18, 5 µm,
50×3.9 mm2). Bracketing standards were made up and run, and the accuracy of the standards was checked.
Standards were injected through the run at least six times. The percentage relative standard deviation of
bracketing standards was <2% throughout the run with excellent linearity (y=0.0021x, R2=0.9998).
Statistics
No formal sample size calculation was performed. On the basis of previous studies, it was anticipated that
nine measurements for each setting (altogether 20 different combinations) would allow the detection of
possible significant differences. The data were not assumed to be normally distributed. In vitro filter dose
values are reported as means, medians and minimum and maximum values. To test for the difference in
in vitro filter dose between the VHCs or between different RRs, we used the Mann–Whitney U-test.
To assess the correlation between VT and in vitro filter dose we used the Spearman rank correlation.
The software IBM SPSS Statistics for Windows, version 24 (IBM Corp, Armonk, NY, USA) was used for
the data analysis.
Results
The effect of tidal volume on drug delivery
There was a strong and statistically significant correlation between VT and in vitro filter dose of salbutamol
with both VHCs at both RRs (figures 2 and 3). The amount of salbutamol available for inhalation
increased almost linearly with VT. For BH (VHC volume 350 mL) the Spearman rank correlation
coefficients were 0.944 (p<0.001) and 0.965 (p<0.001) at RRs of 25·min−1 and 50·min−1 respectively. For
OD (VHC volume 140 mL) the Spearman rank correlation coefficients were 0.893 (p<0.001) at both RRs
(25 min−1 and 50 min−1).
The effect of RR on drug delivery
The median dose of salbutamol recovered was significantly lower at a RR of 25 min−1 compared with a RR
of 50 min−1 except for OD at a VT of 30 mL and 200 mL and for BH at a VT of 50 mL. The lowest
median amount of drug available for inhalation was 1.5 µg for BH with the breathing pattern of RR at
25 min−1 and VT of 30 mL. The highest median amount of drug available for inhalation was 57.7 µg for
OD with a RR of 50 min−1 and VT of 200 mL. Both VHCs showed a 2–3-fold range difference between
the minimum and maximum dose output (table 2).
Dose output difference between VHCs
With a RR of 25 min−1 and the lowest VT of 30 mL there was an approximately 12-fold difference in
median salbutamol doses between BH and OD (1.5 µg versus 18.5 µg; p=0.002). With a higher VT the
difference between VHCs was smaller but remained significant at all VT values and both RRs (table 2).
Discussion
In this study we have demonstrated in a simulation model that breathing pattern has a significant effect on
β2-agonist drug delivery from VHCs. Although the amount of salbutamol recovered from the filter
FIGURE 2 In vitro filter dose of
salbutamol with large valved holding
chamber, Babyhaler (volume 350 mL).
Respiratory rate of 25 min−1 and
50 min−1 and tidal volume from 30
to 200 mL. Rho: Spearman’s rank
correlation coefficient.
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increased with RRs and VT values in both VHCs, there was a marked difference between the two devices
investigated. Compared with OD, the salbutamol output of BH was significantly lower with all breathing
patterns. When BH was used at a VT of 30 mL and a RR of 25·min−1 the salbutamol amount in the filter
was practically zero. There was a 2 to 12-fold difference of delivered dose between BH and OD, favouring
OD with every breathing arrangement.
TABLE 2 In vitro filter dose of salbutamol recovered from the filter with respiratory rate (RR) of
25·min−1 and 50·min−1 and different tidal volume (VT)
BH
OD
BH
OD
0.0+
13.7
2.4
14.5
3.1
13.4
5.7
21.1
25
50
BH
OD
BH
OD
25
50
BH
OD
BH
OD
25
50
BH
OD
BH
OD
25
50
BH
OD
BH
OD
25
50
30
VHCRR min–1VT mL
50
100
150
200
8.8
24.3
11.6
29.4
15.4
23.2
19.8
41.1
15.7
33.7
27.7
32.1
2.5
32.3
5.5
28.3
10.2
24.1
9.5
34.9
16.2
34.2
18.4
40.9
21.9
38.2
32.1
52.3
25.7
49.2
38.5
94.2
1.3§
19.7
3.8
19.3
5.5
19.6
7.6
29.7
11.2
28.7
15.2
35.2
17.9
32.1
27.5
46.0
21.6
42.8
34.2
46.9
1.5§
18.5
In vitro filter dose of salbutamol µg
Minimum Maximum Mean Median
3.5
17.8
4.4
19.5
7.6
29.8
9.6
27.9
15.4
35.0
17.6
33.7
29.2
46.3
23.3
41.6
33.7
57.7
0.004*
p-value¶
0.818
0.088
0.002*
0.041*
0.041*
0.004*
0.002*
<0.001*
0.113
0.002*
p-value#
0.002*
<0.001*
0.002*
0.002*
0.002*
0.002*
0.002*
<0.001*
0.004*
Comparing two valved holding chamber (VHCs): Babyhaler (BH) and Optichamber Diamond (OD).
#: between BH and OD. Mann–Whitney U-test; ¶: RR 25 min−1 and 50 min−1 for the same VHC with the
same VT, Mann–Whitney U-test; +: result is below limit of quantification (LOQ) and detection (LOD); §: result
is below LOQ but above LOD. *: p<0.05.
FIGURE 3 In vitro filter dose of
salbutamol with small valved holding
chamber, Optichamber Diamond
(volume 140 mL). Respiratory rate of
25 min−1 and 50 min−1 and tidal
volume from 30 to 200 mL. Rho:
Spearman’s rank correlation coefficient.
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Since each age group has its own breathing pattern (and the breathing pattern is also different if the child
has bronchial obstruction) it is essential to evaluate drug delivery for each target group. Our study gives
important information with clinical implications about a patient group that is challenging to treat.
Children below school age have very low respiratory flow rates compared with older children and adults,
although in some specific conditions children might have higher VT values than previously thought [18].
We used respiratory patterns that represent children younger than 7 years [5–7]. For example, with a RR
of 25 min−1 and a VT of 100 mL, minute ventilation is as low as 2.5 L·min−1 and sinusoidal approximation
of the breathing profile gives estimates for the mean inspiratory flow rate of 5.0 L·min−1 and PIFR of
7.9 L·min−1. Previous publications have mainly focussed on VT values >150 mL and flow rates of
20–60 L·min−1. Inspiratory flow rates <10 L·min−1 were only used in some studies [8, 10, 11].
By age, minute ventilation is increasing due to overall growth and development (increased height, lung
volume, and alveolar surface area). However, the increase in Vt is not fully revoked by simultaneous
decreases in RR. Therefore, it is likely that in older children, the resting tidal breathing leads to better
deposition through a VHC compared with infants and toddlers. As the VT and RR rises, the aerosol
speed increases and there is less time for the particles to precipitate inside the VHC. Previous studies
also described inhalation volume and flow dependence of drug delivery through VHCs [8, 19, 20–22].
CHAVEZ et al. [11] found that gradually increasing the VT from 36 to 290 mL, the filter dose of albuterol
increased in a logarithmic fashion with both RRs of 12 and 24 L·min−1. MITCHELL et al. [10] observed
marked differences on the effect of breathing patterns between three VHC designs (Space Chamber,
Vent-170 and Child AeroChamber). For example, with a VT of 50 mL and a RR of 30 min−1, one of the
VHCs yielded undetectable levels of salbutamol compared with a 37-µg filter dose from another device.
In our measurements, to collect the drug deposited on the filter, we used eight breathing cycles. In some
studies it was shown that even two cycles was sufficient for reliable collection. However, we wanted to
make sure that the VHC was emptied even using breathing patterns of children under 2 years of age with
a low VT. We used a tI/ttot of 0.5. The tI/ttot is independent of age and varies between 0.3 and 0.5 [5].
Since all measurements were done with the same duty cycle, this parameter does not affect the observed
difference between devices.
To minimise the effect of static charge all VHCs were prewashed with detergent and air dried before use
[3, 19, 23, 24]. Despite standardised and well-controlled conditions, we found a marked difference in the
performance of the two devices used. VHCs on the market differ in volume, shape, material, valve
mechanism and overall design, all of which can influence the aerosol distribution, precipitation pattern,
and drug delivery in an unpredictable fashion [22, 25]. For example, it has been speculated that in a larger
volume VHC, aerosol concentration and particle impaction is less than in smaller volume VHCs, which
results in lower inhaled doses at a small VT but higher doses when the VHC can be emptied faster with a
larger VT. The relatively large dead space in the BH (40 mL) and suboptimal valve function can partly
explain the low VHC output at a small VT [12, 21, 22]. It is not entirely clear why BH performed poorly
compared with OD.
A recent meta-analysis concluded that VHCs are as effective as nebulisers in relieving acute
bronchoconstriction with bronchodilators [26]. However, this review did not include children under the
age of 2 years with a low VT. In addition, two of the three studies using BH favoured nebulisers in contrast
with the overall conclusion of the review. The results of such meta-analyses cannot be generalised to
consider all VHCs as equal for small children in the need of acute inhaled asthma medication. Hence,
different VHCs should not be considered to be interchangeable [27].
The dose response to β2-agonists is relatively shallow [28, 29]. In stable asthma, having a lower respirable
salbutamol dose available may have little consequences. However, in acute settings the observed degree of
drug delivery differences may have serious consequences. This magnitude of performance variability
implies the potential for clinically relevant differences when salbutamol and other inhaled medication are
administered via VHCs. One might argue that by increasing the administered doses one could obtain the
desired therapeutic effect. However, increasing the dose will not necessarily increase the delivered dose
linearly. In addition, this approach is not cost-effective and may increase the risk of side effects. For this
reason, it is a high priority to test each VHC in the intended target population with each type of pMDI.
We used RRs and VT values representing small children in need of acute inhaled medications as the target
population. The parameters were to mimic a real-life setting but in a well-controlled manner. Ideally, drug
delivery should be quantified through the VHC as the patient would actually breathe. In vivo studies are
indispensable; nevertheless in vitro measurements provide reproducibility when evaluating the effect of
tidal breathing, flow, and when comparing different devices.
Our methodology was limited to measuring in vitro total dose delivery. Correlation between in vitro and
in vivo data and clinically relevant therapeutic effects is difficult to predict. VHC output generally
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increases with an increase in inhalation volume and flow [8] and reaches a plateau at around 30 L·min−1,
depending on VHC dimensions [9]. While lung dose also increases with VT, at some point the accelerated
inspiratory flow can eventually have a negative effect on lung dose [21]. We did not evaluate the amount
of drug that potentially would have impacted on the oral cavity, pharynx and upper airways. Nonetheless,
it could be speculated that with the flows we used the plateau of VHC output and in vivo lung deposition
was not an issue. The therapeutic amount of drug reaching the lower airways is probably even smaller
than detected on the filters. For this reason, the differences in devices and their capacity for drug delivery
may be even more significant.
We used a respiratory simulator that produced a sinusoidal form of respiratory cycle. Although VT values
and RRs in our study were comparable with real-life settings, peak inspiratory flow probably differs from
real breathing cycles where inspiratory proportion and curve shape differ from an experimental sinusoidal
pattern. However, there is considerable variation in respiratory patterns between individuals especially
during an acute respiratory distress and even variation between respiratory cycles in the same individual.
Therefore, simulated models can never mimic real-life breathing patterns to the smallest detail.
Part of the variation in our results may be due to the function of the pMDI itself (Ventolin Evohaler) and
HPLC analysis method of the drug delivery. However, these factors affect each respiratory pattern and
both VHCs tested similarly and cannot explain the detected differences in drug delivery between different
breathing patterns and devices.
Conclusions
In our financially independent in vitro study, we found a marked difference in salbutamol delivery
between the two VHCs studied (BH and OD). The delivered filter dose of both VHCs increased with
increasing VT and RR. BH performed especially poorly with a VT <150 mL. In small children with asthma
exacerbation having a very low VT, there might be close to zero amount of the drug available for
inhalation. When training physicians and caregivers, there should be more emphasis on how breathing
patterns affect drug delivery and eventually the success of treatment when using VHCs in small children.
Instead of considering all VHCs as equal, all combinations of pMDI+VHC should be systematically tested
in order to establish the most effective and reliable combinations to be licensed for clinical practice.
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